Drug Development

A startup led by ex-Novo Nordisk execs plans a reverse takeover to fund its made-in-Canada generic Ozempic, aiming to disrupt a C$3.5B market.

A French biotech's breakthrough in topical mRNA delivery could turn skin into a programmable interface, disrupting dermatology and the multi-billion dollar beauty industry.

With spending up and losses widening, CG Oncology is leveraging its $1B cash reserve to push its promising bladder cancer drug toward a Q4 FDA submission.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

Opal Therapeutics' organoid platform, backed by a major NSF award, bypasses failed animal models to fast-track cures for endometriosis and fibroids.

Actimed Therapeutics reclaims S-oxprenolol, a promising ALS drug. This isn't just a pipeline shuffle; it's a calculated move to dominate the future of muscle health.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

Phoenix Nest secures a pivotal $3M NIH grant to manufacture a potential cure for Sanfilippo syndrome, a fatal childhood disease with no current treatment.